CVS HEALTH Corp
$88.59
−1.20 (−1.34%) · delayed · Nov 16, 2026
Five-year price
52w $69.51 to $110.68
- Market cap
- $113.3B
- Enterprise value
- $165.4B
- P/E
- 63.7×
- 23.1× on 3y avg EPS
- EV / EBIT
- 35.5×
- FCF yield
- 6.9%
- ROIC
- 3.0%
- Debt / equity
- 0.80
- Piotroski F
- 6/9
Value scorecard · FY2025
Does it pass the value tests?
Quality
- ○ROIC > 12% (5y avg)5y avg ROIC 6.0%
- ○ROE > 15% (5y avg)5y avg ROE 7.2%
- ●Stable operating marginsMargin volatility 1.2% (σ, 5y)
- ●Earnings convert to cashFCF / net income 242% (5y avg)
- ●Growing revenueRevenue CAGR 5y 8.4%
- ●Shrinking share countDiluted shares -3.3% over 5y
Value
- ○P/E below 15P/E 63.7
- ○EV/EBIT below 12EV/EBIT 35.5
- ●FCF yield above 6%FCF yield 6.9%
- ○Price below Graham NumberGraham Number $42.88
- ●P/B below 3P/B 1.5
Safety
- ○Debt / equity below 0.5D/E 0.80
- ○Debt payable in < 4 yrs of earningsNet debt $52.0B
- ○Interest coverage > 8xCoverage 1.5x
- ○Current ratio > 1.5Current ratio 0.84
- ●Piotroski F-score ≥ 6F-score 6/9
Graham Defensive
- ●Adequate size (revenue > $2B)Revenue $402.1B
- ○Strong condition (current ratio ≥ 2)Current ratio 0.84
- ○Earnings stability (no loss, 10y)10 years of data
- ●Uninterrupted dividendsDividends paid every year on record
- ○Earnings growth ≥ 33% (10y, 3y avgs)EPS growth 7%
- ○Moderate P/E (≤ 15 on 3y avg EPS)P/E (3y avg) 23.1
- ○P/E × P/B ≤ 22.5Product 34.8
Valuation lab
What do you have to believe?
At $88.59, the market is pricing in about 6.4% annual free-cash-flow growth for the next decade (9% discount rate, 2.5% terminal growth).
Starting cash flow
Net debt $52.0B · 1279M shares · 5y revenue CAGR 8.4%
Intrinsic value
$105.09
Price
$88.59
Margin of safety
16%
What the price implies
The market is paying for 6.4% annual cash-flow growth for 10 years at a 9.0% discount rate.
Terminal value share
60% of the value sits beyond year 10.
Financial statements
A decade of the record.
USD millions · fiscal years · source: SEC 10-K XBRL
| Line item | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 177,526 | 184,765 | 193,919 | 256,776 | 268,706 | 292,111 | 322,467 | 357,776 | 372,809 | 402,067 |
| Gross profit | 28,857 | 28,545 | — | — | — | — | — | — | — | — |
| Operating income | 10,386 | 9,538 | 4,021 | 11,987 | 13,911 | 13,310 | 7,954 | 13,743 | 8,516 | 4,660 |
| Operating margin | 5.9% | 5.2% | 2.1% | 4.7% | 5.2% | 4.6% | 2.5% | 3.8% | 2.3% | 1.2% |
| Pre-tax income | 8,637 | 8,268 | 1,406 | 8,997 | 9,770 | 10,537 | 5,836 | 11,173 | 6,148 | 2,136 |
| Income tax | 3,317 | 1,637 | 2,002 | 2,366 | 2,569 | 2,548 | 1,509 | 2,805 | 1,562 | 408 |
| Net income | 5,317 | 6,622 | (594) | 6,634 | 7,179 | 8,001 | 4,311 | 8,344 | 4,614 | 1,768 |
| EPS (diluted) | 4.90 | 6.44 | -0.57 | 5.08 | 5.46 | 6.02 | 3.26 | 6.47 | 3.66 | 1.39 |
| Diluted shares | 1,079 | 1,024 | 1,044 | 1,305 | 1,314 | 1,329 | 1,323 | 1,290 | 1,262 | 1,271 |
Who owns it